Calithera Biosciences, Inc. (NASDAQ:CALA) Downgraded to “Sell” at BidaskClub
BidaskClub cut shares of Calithera Biosciences, Inc. (NASDAQ:CALA) from a hold rating to a sell rating in a report published on Friday.
A number of other research firms also recently issued reports on CALA. Zacks Investment Research downgraded Calithera Biosciences from a buy rating to a hold rating in a research report on Thursday, July 13th. HC Wainwright reissued a buy rating and set a $19.00 price target (up previously from $14.00) on shares of Calithera Biosciences in a research report on Monday, June 12th. Wells Fargo & Company restated an outperform rating and set a $20.00 price objective (up previously from $15.00) on shares of Calithera Biosciences in a report on Tuesday, June 6th. Finally, Leerink Swann restated an outperform rating and set a $16.00 price objective on shares of Calithera Biosciences in a report on Monday, April 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Calithera Biosciences presently has a consensus rating of Hold and an average target price of $15.50.
Calithera Biosciences (NASDAQ:CALA) opened at 15.30 on Friday. The company’s 50-day moving average price is $15.95 and its 200 day moving average price is $12.29. The firm’s market capitalization is $540.00 million. Calithera Biosciences has a 52-week low of $2.20 and a 52-week high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last posted its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.14. The business had revenue of $4.19 million for the quarter, compared to the consensus estimate of $1.40 million. Equities analysts predict that Calithera Biosciences will post ($0.89) earnings per share for the current fiscal year.
WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/calithera-biosciences-inc-nasdaqcala-downgraded-to-sell-at-bidaskclub/1465651.html.
In other news, VP Keith Orford sold 2,120 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $18.31, for a total transaction of $38,817.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold 3,470 shares of company stock worth $61,817 in the last ninety days. Insiders own 16.30% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP acquired a new position in shares of Calithera Biosciences during the first quarter valued at $47,550,000. FMR LLC raised its stake in Calithera Biosciences by 278.2% in the first quarter. FMR LLC now owns 1,462,190 shares of the biotechnology company’s stock valued at $16,888,000 after buying an additional 1,075,592 shares during the period. RA Capital Management LLC purchased a new stake in Calithera Biosciences during the first quarter valued at approximately $8,374,000. Bogle Investment Management L P DE purchased a new stake in Calithera Biosciences during the first quarter valued at approximately $5,732,000. Finally, Vanguard Group Inc. raised its stake in Calithera Biosciences by 99.8% in the first quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock valued at $10,684,000 after buying an additional 462,137 shares during the period. 54.65% of the stock is currently owned by institutional investors.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.